Georgetown Cardiology Fellows(@GTCardFellows) 's Twitter Profileg
Georgetown Cardiology Fellows

@GTCardFellows

Cardiovascular Disease Fellowship at @GUmedicine & @MedStarWHC. Tweets & RTs are not endorsements.

ID:1292083148973637639

linkhttps://t.ly/603y calendar_today08-08-2020 13:01:05

636 Tweets

962 Followers

275 Following

Georgetown Cardiology Fellows(@GTCardFellows) 's Twitter Profile Photo

Congratulations to fellows Ryan Wallace, Andrew Hill & Ilan Merdler, IC faculty Brian C. Case, MD Hayder Hashim Itsik Ben Dor Ron Waksman on their pub highlighting the clinical and economic impact of coronary microvascular dysfunction.

👇
sciencedirect.com/science/articl…

account_circle
Syed Waqas Haider, MD, MPH, FACC(@WaqasHaiderMD) 's Twitter Profile Photo

Closing out strong with an incredible panel delving into imaging in cardiorheum, vasculitis & pericardial disease! 🔥🫀 Exciting opportunities lie ahead as data supports their use for dx, prognosis, & mgmt in this complex pt cohort. American College of Cardiology

Closing out #ACC2024 strong with an incredible panel delving into imaging in cardiorheum, vasculitis & pericardial disease! 🔥🫀 Exciting opportunities lie ahead as data supports their use for dx, prognosis, & mgmt in this complex pt cohort. @ACCinTouch
account_circle
Andrew Hill(@andrew_p_hill) 's Twitter Profile Photo

Great first . Enjoyed finally meeting the American College of Cardiology and seeing their great work this year. Wonderful to meet new and old friends. And honored to present work from MedStar Health Georgetown Cardiology Fellows regarding MCS as well as conduction abnormalities after TAVR.

Great first #ACC24. Enjoyed finally meeting the @ACCinTouch #ACCYoungScholars and seeing their great work this year. Wonderful to meet new and old friends. And honored to present work from @MedStarHealth @GTCardFellows regarding MCS as well as conduction abnormalities after TAVR.
account_circle
American College of Cardiology(@ACCinTouch) 's Twitter Profile Photo

The PREVENT trial showed that preventive of focal non-FFR-positive plaques that are angiographically >50% & have evidence of vulnerability on intravascular imaging along w/ OMT is superior to OMT for clinical outcomes at 2 years.

Read more: bit.ly/3xuHWrl

The PREVENT trial showed that preventive #PCI of focal non-FFR-positive plaques that are angiographically >50% & have evidence of vulnerability on intravascular imaging along w/ OMT is superior to OMT for clinical outcomes at 2 years. Read more: bit.ly/3xuHWrl #ACC24
account_circle
Duk-Woo Park(@dukwoo_park) 's Twitter Profile Photo

A long-waited PREVENT trial is now presented at LBCT-V
🇰🇷From the inception of trial to completion of trial took a decade.
✅1,606 pts with intracoronary imaging-detected “Vulnerable Plaque” randomized 1:1 to (1) Preventive PCI vs (2) OMT alone.
✅Prevent PCI…

account_circle
NEJM(@NEJM) 's Twitter Profile Photo

Presented today at :

In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t

Presented today at #ACC24: In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: nej.md/3xyXU3t
account_circle
NEJM(@NEJM) 's Twitter Profile Photo

In the SMART trial of TAVR in patients with a small aortic annulus, a self-expanding valve was noninferior to a balloon-expandable valve for clinical outcomes and was superior for bioprosthetic-valve dysfunction through 12 months. Full results: nej.md/49p7VO7

In the SMART trial of TAVR in patients with a small aortic annulus, a self-expanding valve was noninferior to a balloon-expandable valve for clinical outcomes and was superior for bioprosthetic-valve dysfunction through 12 months. Full results: nej.md/49p7VO7 #ACC24
account_circle
NEJM(@NEJM) 's Twitter Profile Photo

Original Article: Empagliflozin after Acute Myocardial Infarction (EMPACT-MI) nej.md/4cEb6EB

Editorial: Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment nej.md/3vFF1LK

American College of Cardiology

Original Article: Empagliflozin after Acute Myocardial Infarction (EMPACT-MI) nej.md/4cEb6EB Editorial: Decreasing the Risk of Heart Failure in a Changing Post–Myocardial Infarction Environment nej.md/3vFF1LK @ACCinTouch #ACC24
account_circle
NEJM(@NEJM) 's Twitter Profile Photo

Presented at :

Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: nej.md/4akVhRx

Presented at #ACC24: Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: nej.md/4akVhRx
account_circle